Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes

NCT00398047 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: Azacitadine and Hematopoietic Growth Factors

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]